NEW YORK — Biognosy said on Tuesday that it has entered a strategic agreement with Siemens Healthineers for the discovery and development of protein biomarkers.
Under the agreement, the firms will use Schlieren, Switzerland-based Biognosys' mass spectrometry technology to discover novel biomarkers, which they will then validate for potential clinical applications including clinical trials and in vitro diagnostics.
The companies will run the project out of Siemens Healthineers' clinical laboratory in Berkeley, California.
"With this agreement we can enable our biopharmaceutical customers to use the power of our proprietary discovery proteomics solution for novel biomarker identification and bring these biomarkers into clinical applications with Siemens Healthineers’ diagnostic assay development expertise," Oliver Rinner, Biognosys' founder and CEO, said in a statement.
"We are excited about this relationship with Biognosys because their expertise and unique biomarker discovery capabilities are very complementary to our end-to-end diagnostic solutions for our biopharmaceutical customers," said Sebastian Kronmueller, head of the Siemens Healthcare Laboratory in California.